PBI-4050 sodium salt (Setogepram (sodium salt)) (Synonyms: Setogepram sodium; PBI-4050 sodium) |
| Catalog No.GC31698 |
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1254472-97-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PBI-4050 acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84.
PBI-4050, a synthetic analogue of a medium-chain length fatty acid, binds to FFA receptor 1 (FFAR1/GPR40) and GPR84. To determine the potential role of PBI-4050 on diabetic kidney disease, The accelerated model of type 2 diabetic nephropathy, eNOS-/- db/db mice are utilized. Mice are treated with either vehicle or PBI-4050 (100 mg/kg) by daily gavage from 8-20 weeks of age. eNOS-/- db/db mice are moderately hypertensive, and PBI-4050 has no effect on blood pressure. Furthermore, compared with vehicle-treated mice, which exhibit a decrease in glomerular filtration rate (GFR) from 8-20 weeks, PBI-4050 preserves GFR. Podocyte number per glomerulus section markedly decreases from 8-20 weeks of age in vehicle-treated mice, while PBI-4050 treatment significantly slows this loss[1].
[1]. Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *